LinkedIn · Mar 2026
Serinus added Daniel Nomura to its Scientific Advisory Board to help advance the ApoXY platform and therapeutic pipeline in molecular glues and targeted protein degradation.
Combinations therapy by rational design
Company research
Public company, workplace, funding, and market signals
Overview
Serinus Biosciences is a New York-based biotechnology company developing AI-driven protein-interaction drug discovery and combination-therapy technologies for oncology and immunology. Its public materials emphasize interactome foundation models, the ApoXY platform, and a Pep-to-Mol workflow to find druggable vulnerabilities in tumor resistance.
Primary product
ApoXY platform for protein-interaction drug discovery and molecular-glue therapeutics
Founded
2022
Headquarters
New York, New York, United States
Team size
1-10
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
AI drug discovery / oncology therapeutics
Offices
Open Positions
0 jobs at Serinus Biosciences
No open positions
Check back later for new openings